PerkinElmer's $400 Mil. NEN Buy Highlights Build In Genomics M&A Activity
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of NEN Life Sciences from the private equity investment firm Genstar Capital LLC for approximately $400 mil. will expand PerkinElmer's life sciences business and broaden the company's functional genomics and high-throughput screening offerings.